Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00071838 (ClinicalTrials.gov)	October 30, 2003	31/10/2003	Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis	Zenapax (Daclizumab) Admin to Pts With Multiple Sclerosis (ZAP MS): Effect of Intravenously Admin Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (Daclizumab) on Inflammatory Activity in the Central Nervous System	Multiple Sclerosis, Relapsing-Remitting	Drug: Daclizumab	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	18 Years	65 Years	All	16	Phase 2	United States
2	NCT00001934 (ClinicalTrials.gov)	September 1999	3/11/1999	Zenapax to Treat Multiple Sclerosis	Effect of the Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (IL-2R-Alpha; Zenapax(Registered Trademark)) on Inflammatory Activity in the CNS in MS in a Baseline-to-Treatment, Cross-Over, MRI-Controlled Single Center Phase I/II Trial	Multiple Sclerosis	Drug: Zenapax	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	18 Years	65 Years	Both	22	Phase 2	United States